In line with development of anti‐cancer therapeutic approaches to selectively target IL13Rα2 such as a chimeric fusion protein consisting of IL‐13 and truncated Pseudomonas exotoxin (IL‐13‐PE),28, 29 we generated a scFv for anti‐IL‐13Rα2 antibody by the phage display technology, which specifically recognised IL‐13Rα2 on tumour cell surfaces, with a high binding activity and specificity and fused with truncated Pseudomonas exotoxin (scFvIL‐13Rα2‐PE).30 The gene discussed is IL13; the disease is neoplasm.